1. Bioorg Med Chem Lett. 2008 Feb 15;18(4):1402-6. doi:
10.1016/j.bmcl.2008.01.010.  Epub 2008 Jan 8.

Potent, selective MCH-1 receptor antagonists.

Erickson SD(1), Banner B, Berthel S, Conde-Knape K, Falcioni F, Hakimi I, 
Hennessy B, Kester RF, Kim K, Ma C, McComas W, Mennona F, Mischke S, Orzechowski 
L, Qian Y, Salari H, Tengi J, Thakkar K, Taub R, Tilley JW, Wang H.

Author information:
(1)Discovery Chemistry, Hoffmann-La Roche, Inc., 340 Kingsland Street, Nutley, 
NJ 07110, USA.

This paper describes the lead optimization of a new series of potent, selective, 
orally bioavailable, brain-penetrant MCH-1 receptor antagonists. A major focus 
of the work was to achieve a selectivity profile appropriate for in vivo 
efficacy studies and safety.

DOI: 10.1016/j.bmcl.2008.01.010
PMID: 18243691 [Indexed for MEDLINE]
